Seragy launches with €12 million financing to advance quantitative biomarkers for neurodegenerative diseases
seragy holding GmbH (formerly Prosperodes GmbH), a biomarker strategy company focused on neurodegenerative diseases and other proteopathies, has secured €12 million in funding to accelerate the development of its SeRAS® platform (Seed Replication, Analysis and Subtyping) and expand its laboratory and analytical capabilities. The financing is backed by Commerzbank, the Mittelständische…
Read original article on The Medical News →Related news
-
Before Jules Verne, Edgar Allan Poe imagined the Space Age
-
Protein Powder Prices Are Skyrocketing. Use These<b><strong> </strong></b>Smart Strategies to Save Money and Maintain Muscle.
-
Wearable cyborg training linked to longer walking distances in people with ALS
-
AI misuse and nuclear famine could threaten humanity's survival before 2100
-
Jawbone necrosis in advanced breast cancer: Study highlights the importance of oral health
-
Netinho e anabolizantes: entenda polêmica com médico que tratou o cantor
-
The crucial responsibilities doctors must never offshore to AI
-
Common asthma drug improves strength in children with muscle disease